TherapeuticsMD Analyst Ratings
TherapeuticsMD Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/17/2023 | 39.66% | Cantor Fitzgerald | → $5 | Reiterates | Neutral → Neutral |
| 01/11/2023 | 39.66% | Cantor Fitzgerald | → $5 | Reinstates | → Neutral |
| 07/13/2022 | -72.07% | Cantor Fitzgerald | → $1 | Reiterates | → Neutral |
| 06/07/2022 | 179.33% | HC Wainwright & Co. | → $10 | Downgrades | Buy → Neutral |
| 05/06/2022 | -72.07% | Cantor Fitzgerald | $5 → $1 | Downgrades | Overweight → Neutral |
| 03/11/2022 | -30.17% | HC Wainwright & Co. | $3 → $2.5 | Maintains | Buy |
| 11/12/2021 | -16.2% | HC Wainwright & Co. | $4 → $3 | Maintains | Buy |
| 08/07/2020 | -66.48% | Jefferies | $1.25 → $1.2 | Downgrades | Hold → Underperform |
| 05/19/2020 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 05/07/2020 | 39.66% | HC Wainwright & Co. | $6 → $5 | Reiterates | → Buy |
| 04/16/2020 | 318.99% | Stifel | $14 → $15 | Maintains | Buy |
| 02/21/2020 | 67.6% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/17/2023 | 39.66% | 坎托·菲茨杰拉德 | → 5 美元 | 重申 | 中性 → 中性 |
| 2023 年 11 月 1 日 | 39.66% | 坎托·菲茨杰拉德 | → 5 美元 | 恢复 | → 中立 |
| 07/13/2022 | -72.07% | 坎托·菲茨杰拉德 | → 1 美元 | 重申 | → 中立 |
| 2022 年 7 月 6 日 | 179.33% | HC Wainwright & Co. | → 10 美元 | 降级 | 买入 → 中性 |
| 2022 年 6 月 5 日 | -72.07% | 坎托·菲茨杰拉德 | 5 美元 → 1 美元 | 降级 | 超重 → 中性 |
| 03/11/2022 | -30.17% | HC Wainwright & Co. | $3 → 2.5 美元 | 维护 | 买 |
| 11/12/2021 | -16.2% | HC Wainwright & Co. | 4 美元 → 3 美元 | 维护 | 买 |
| 08/07/2020 | -66.48% | 杰富瑞集团 | 1.25 美元 → 1.2 美元 | 降级 | 持有 → 表现不佳 |
| 2020 年 5 月 19 日 | — | 摩根大通 | 降级 | 超重 → 中性 | |
| 05/07/2020 | 39.66% | HC Wainwright & Co. | 6 美元 → 5 美元 | 重申 | → 购买 |
| 2020 年 4 月 16 日 | 318.99% | Stifel | 14 美元 → 15 美元 | 维护 | 买 |
| 02/21/2020 | 67.6% | HC Wainwright & Co. | 7 美元 → 6 美元 | 维护 | 买 |
What is the target price for TherapeuticsMD (TXMD)?
TherapeicsMD（TXMD）的目标价格是多少？
The latest price target for TherapeuticsMD (NASDAQ: TXMD) was reported by Cantor Fitzgerald on August 17, 2023. The analyst firm set a price target for $5.00 expecting TXMD to rise to within 12 months (a possible 39.66% upside). 2 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2023年8月17日公布了TherapeicsMD（纳斯达克股票代码：TXMD）的最新目标股价。该分析公司将目标股价定为5.00美元，预计TXMD将在12个月内上涨至39.66％（可能上涨39.66％）。去年，有2家分析公司公布了评级。
What is the most recent analyst rating for TherapeuticsMD (TXMD)?
TherapeicsMD（TXMD）的最新分析师评级是多少？
The latest analyst rating for TherapeuticsMD (NASDAQ: TXMD) was provided by Cantor Fitzgerald, and TherapeuticsMD reiterated their neutral rating.
坎托·菲茨杰拉德提供了TherapeicsMD（纳斯达克股票代码：TXMD）的最新分析师评级，TherapeicsMD重申了中性评级。
When is the next analyst rating going to be posted or updated for TherapeuticsMD (TXMD)?
TherapeicsMD（TXMD）的下一份分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TherapeuticsMD, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TherapeuticsMD was filed on August 17, 2023 so you should expect the next rating to be made available sometime around August 17, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括阅读公开财务报表、与TherapeicsMD的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。TherapeicsMD的最后一次评级是在2023年8月17日提交的，因此你应该预计下一个评级将在2024年8月17日左右公布。
Is the Analyst Rating TherapeuticsMD (TXMD) correct?
分析师评级 TherapeicsMD (TXMD) 是否正确？
While ratings are subjective and will change, the latest TherapeuticsMD (TXMD) rating was a reiterated with a price target of $0.00 to $5.00. The current price TherapeuticsMD (TXMD) is trading at is $3.58, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但重申了最新的TherapeicsMD（TXMD）评级，目标股价为0.00美元至5.00美元。TherapeicsMD（TXMD）目前的交易价格为3.58美元，在分析师的预测区间内。